Literature DB >> 23913486

Candidate gene association study implicates p63 in the etiology of nonsyndromic bladder-exstrophy-epispadias complex.

Lihong Qi1, Mei Wang, Garima Yagnik, Manuel Mattheisen, John P Gearhart, Yegappan Lakshmanan, Anne-Karolin Ebert, Wolfgang Rösch, Michael Ludwig, Markus Draaken, Heiko Reutter, Simeon A Boyadjiev.   

Abstract

BACKGROUND: Bladder-exstrophy-epispadias complex (BEEC) is a severe congenital anomaly that represents a spectrum of urological abnormalities where parts or all of the distal urinary tract fail to close during development. Multiple lines of evidence strongly suggested p63 as a plausible candidate gene. We conducted a candidate gene association study to further investigate the role of p63 in human BEEC.
METHODS: We conducted a family-based association study of p63 using 154 Caucasian patients with nonsyndromic BEEC and their unaffected parents. High throughput single nucleotide polymorphism (SNP) genotyping was carried out using Illumina's Golden Gate Assay for 109 selected tagging SNPs localized within p63 with a minor allele frequency > 0.01. Individual and haplotype SNP transmission disequilibrium tests were conducted using Plink and Haploview, respectively. We also examined parent-of-origin effects using paternal asymmetry tests implemented in FAMHAP (http://famhap.meb.uni-bonn.de/index.html).
RESULTS: Nominally significant associations were identified between BEEC and six SNPs (rs17447782, rs1913720, rs6790167, rs9865857, rs1543969, rs4687100), and four haplotype blocks including or near these significant SNPs. Analysis of parent-of-origin effects showed significant results for seven SNPs (rs4118375, rs12696596, rs6779677, rs13091309, rs7642420, rs1913721, and rs1399774). None of these results remained significant after multiple testing correction.
CONCLUSION: The altered transmission of p63 variants in nonsyndromic BEEC patients may be suggestive of its involvement in the disease etiology. Further and large multi-institutional collaborative studies are required to elucidate the role of p63 in nonsyndromic BEEC.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  BEEC; association study; bladder exstrophy; candidate gene; case-parent trio; epispadias; p63

Mesh:

Substances:

Year:  2013        PMID: 23913486     DOI: 10.1002/bdra.23161

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  5 in total

1.  Role of the LF-SINE-Derived Distal ISL1 Enhancer in Patients with Classic Bladder Exstrophy.

Authors:  Rong Zhang; Michael Knapp; Franziska Kause; Heiko Reutter; Michael Ludwig
Journal:  J Pediatr Genet       Date:  2017-04-21

Review 2.  The Genomic Architecture of Bladder Exstrophy Epispadias Complex.

Authors:  Glenda M Beaman; Raimondo M Cervellione; David Keene; Heiko Reutter; William G Newman
Journal:  Genes (Basel)       Date:  2021-07-28       Impact factor: 4.096

3.  Clinical and risk factor analysis of cloacal defects in the National Birth Defects Prevention Study.

Authors:  Kim M Keppler-Noreuil; Kristin M Conway; Dereck Shen; Anthony J Rhoads; John C Carey; Paul A Romitti
Journal:  Am J Med Genet A       Date:  2017-09-28       Impact factor: 2.802

4.  Genetics of Bladder-Exstrophy-Epispadias Complex (BEEC): Systematic Elucidation of Mendelian and Multifactorial Phenotypes.

Authors:  Heiko Reutter; Kim Keppler-Noreuil; Catherine E Keegan; Holger Thiele; Gen Yamada; Michael Ludwig
Journal:  Curr Genomics       Date:  2016-02       Impact factor: 2.236

5.  Genome-wide association study and meta-analysis identify ISL1 as genome-wide significant susceptibility gene for bladder exstrophy.

Authors:  Markus Draaken; Michael Knapp; Tracie Pennimpede; Johanna M Schmidt; Anne-Karolin Ebert; Wolfgang Rösch; Raimund Stein; Boris Utsch; Karin Hirsch; Thomas M Boemers; Elisabeth Mangold; Stefanie Heilmann; Kerstin U Ludwig; Ekkehart Jenetzky; Nadine Zwink; Susanne Moebus; Bernhard G Herrmann; Manuel Mattheisen; Markus M Nöthen; Michael Ludwig; Heiko Reutter
Journal:  PLoS Genet       Date:  2015-03-12       Impact factor: 5.917

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.